Immune response at implant site

The "immune response at implant site" describes the innate and adaptive immune activation when a biomaterial or medical implant is introduced into the body. This process involves the recruitment and activation of cells such as neutrophils, macrophages, dendritic cells, T cells, and B cells at the implantation site, leading to inflammation, cytokine and chemokine release, and, in some cases, the formation of foreign body giant cells. These responses are critical for wound healing and tissue integration, but excessive or dysregulated immune activation can cause chronic inflammation, fibrosis, implant loosening, or failure. Engineering strategies for implants increasingly focus on modulating this response to improve biocompatibility, longevity, and function, for example, by using immunomodulatory coatings or incorporating drugs/intermediates that steer immune cell polarization towards tissue repair rather than chronic inflammation.

Other names

Foreign body response at implant siteInflammatory response at implant interfaceImplant-associated immune activation

Suppression of local immune activation (e.g., via immunomodulatory coatings on implants); Local release of anti-inflammatory cytokines or metabolites; Inhibition of specific immune cell recruitment or activation.